CHCWM – Cancer & Hematology Centers of West Michigan

CPG-03-101 (Compugen)

A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination with BMS-986207 (Anti-TIGIT antibody) and Nivolumab in Subjects with Advanced Solid Tumors